CA2396227A1 - 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation - Google Patents

1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation Download PDF

Info

Publication number
CA2396227A1
CA2396227A1 CA002396227A CA2396227A CA2396227A1 CA 2396227 A1 CA2396227 A1 CA 2396227A1 CA 002396227 A CA002396227 A CA 002396227A CA 2396227 A CA2396227 A CA 2396227A CA 2396227 A1 CA2396227 A1 CA 2396227A1
Authority
CA
Canada
Prior art keywords
benzimidazol
oxy
phenyl
hexanoic acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002396227A
Other languages
French (fr)
Other versions
CA2396227C (en
Inventor
Joachim Kuhnke
Wolfgang Halfbrodt
Ursula Moenning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2396227A1 publication Critical patent/CA2396227A1/en
Application granted granted Critical
Publication of CA2396227C publication Critical patent/CA2396227C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

1,2-Diarylbenzimidazoles of general formula (I) and the use of benzimidazole derivatives for the production of pharmaceutical agents for treatment and prophylaxis of diseases that are associated with a microglia activation are described.
(see formula I)

Claims (24)

1.
in which R1 means a monocyclic or bicyclic C6-12 aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-4 heteroatoms selected from the group that consists of N, S or O, whereby the above-mentioned aryl or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:
F, Cl, Br, I, C(NH)NH2, C(NH)NHR4, C(NH)NR4R4, C(NR4)NH2, C(NR4)NHR4, C(NR4)NR4R4, XOH, XOR4, XOCOR4, XOCONHR4, XOCOOR4, XCOR4, XC (NOH) R4, XC (NOR4) R4', XC (NO(COR4))R4' XCN, XCOOH, XCOOR4, XCONH2, XCONR4R4', XCONHR4, XCONHOH, XCONHOR4, XCOSR4, XSR4, XSOR4, XSO2R4, SO2NH2, SO2NHR4, SO2NR4R4', NO2, XNH2, XNHR4, XNR4R4', XNHSO2R4, XN(SO2R4)SO2R4', XNR4SO2R4', XNHCOR4, XNHCOOR4, XNHCONHR4, tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl,
2,7-dihydro-2,7-dioxoisoindol-1-yl, R4, whereby two substituents at R1, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl, R2 means a monocyclic or bicyclic C6-10 aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-4 heteroatoms selected from the group that consists of N, S or O, whereby the above-mentioned aryl or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:
F, Cl, Br, I, XOH, XOR4, XOCOR4, XOCONHR4, XOCOOR4, XCOR4, XC(NOH)R4, XC(NOR4)R4', XC(NO(COR4))R4', XCOOH, XCOOR4, XCONH2, XCONHR4, XCONR4R4', XCONHOH, XCONHOR4, XCOSR4, XSR4, XSOR4, XSO2R4, SO2NH2, SO2NHR4, SO2NR4R4', NO2, XNHR4, XNR4R4', XNHSO2R4, XN(SO2R4) SO2R4', XNR4SO2R4', tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisoindol-1-yl, R4, whereby two substituents at R2, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediyl-bisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl, R3 means one or two substituents, which form, independently of one another:
hydrogen, F, Cl, Br, I, XOH, XOR4, XOCOR4, XOCONHR4, XOCOOR4, XCOR4, XC(NOH)R4, XC(NOR4)R4', XC(NO(COR4))R4', XCN, XCOOH, XCOOR4, XCONH2, XCONHR4, XCONR4R4', XCONHOH, XCONHOR4, XCOSR4, XSR4, XSOR4, XSO2R4, SO2NH2, SO2NHR4, SO2NR4R4', NO2, XNH2, XNHR4, XNR4R4', XNHSO2R4, XNR4SO2R4', XN(SO2R4)(SO2R4'), XNHCOR4, XNHCOOR4, XNHCONHR4, tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisoindol-1-yl, or R3 can be R4, whereby two substituents at R3, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl, R4 and R4', independently of one another, mean C1-4 perfluoroalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkinyl, C3-cycloalkyl, (C1-3 alkyl-C3-7 cycloalkyl), C1-3 alkyl-C6-10 - aryl, C1-3 alkyl-5 to 10-membered heteroaryl, with 1-4 N, S or O atoms, C6-10aryl or 5- to 10-membered heteroaryl with 1-4 N, S or O atoms, whereby the aryl and heteroaryl groups can be substituted with one or two substituents from the group that consists of F, Cl, Br, CH3, C2H5, NO2, OCH3, OC2H5, CF3, C2F5 or else can carry an annelated methanediylbisoxy group or ethane-1,2-diylbisoxy group, and in addition in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C1-3 alkyl or C1-3 alkanoyl, R5 and R5', independently of one another, mean C1-6 alkyl, C2-6 alkenyl, C2-6 alkinyl, whereby a carbon atom can be exchanged for O, S, SO, SO2, NH, N C1-3 alkyl or N C1-3 alkanoyl, C3-7 cycloalkyl-CO-3 alkyl, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C1-3 alkyl or C1-3 alkanoyl, C6-10 aryl or 5- to 10-membered heteroaryl with 1-4 heteroatoms from N, S, and O, whereby the above-mentioned alkyl, alkenyl and alkinyl chains can be substituted with one of the previously mentioned cycloalkyls, aryls or heteroaryls, whereby all previously mentioned alkyl and cycloalkyl radicals with up to two substituents consisting of CF3, C2F5, OH, O C1-3 alkyl, NH2, NH C1-3 alkyl, NH C1-3 alkanoyl, N(C1-3 alkyl)2, N(C1-3 alkyl)(C1-3 alkanoyl), COOH, CONH2, COO C1-3 alkyl and all previously mentioned aryl and heteroaryl groups can be substituted with one or two substituents from the group that consists of F, Cl, Br, CH3, C2H5, NO2, OCH3, OC2H5, CF3, C2F5 or else can carry an annelated methanediylbisoxy, ethane-1,2-diylbisoxy group, or R5 and R5' together with the nitrogen atom form a 5-to 7-membered heterocyclic compound, which can contain another oxygen, nitrogen or sulfur atom and can be substituted with C1-4 alkyl, C1-4 alkoxy-C0-2 alkyl, C1-4 alkoxy-carbonyl, aminocarbonyl or phenyl, A means C1-10 alkanediyl, C2-10 alkenediyl, C2-10 alkinediyl, (C0-5 alkanediyl-C3-7 cycloalkanediyl-C0-5 alkanediyl), whereby in a 5-membered cyeloalkyl ring, a ring member can be an N or an 0, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N
and/or O, whereby ring nitrogens optionally can be substituted with C1-3 alkyl or C1-3 alkanoyl, whereby in the above-mentioned aliphatic chains, a carbon atom or two carbon atoms can be exchanged for O, NH, N C1-3 alkyl, N C1-3 alkanoyl, and whereby alkyl or cycloalkyl groups can be substituted with up to two substituents consisting of =O, OH, O C1-3 alkyl, NH2, NH
C1-3 alkyl, NH C1-3 alkanoyl, N(C1-3 alkyl)2, N(C1-3 alkyl) (C1-3 alkanoyl), B means COOH, COOR5, CONH5, CONHNH2, CONHR5, CONR5R5', CONHOH, CONHOR5, SO3H, SO2NH2, SO2NHR5, SO2NR5R5', PO3H, PO(OH)(OR5), PO(OR5)(OR5'), PO(OH)(NHR5).
PO(NHR5)(NHR5').
tetrazolyl, in each case bonded to a carbon atom of group A, or the entire group Y-A-B N (SO2R4)(SO2R4') or NHSO2R4, Z means a bond, CH2, (CH2)2, CH(CH3), (CH2)3, CH(CH2CH3), CH(CH3)CH2, CH2CH(CH3), Y means O, NH, NR4, NCOR4, NSO2R4, provided that if Y means NH, NR4, NCOR4 or NSO2R4, and a) substituent R2 contains a nitrogen-containing, saturated heterocyclic compound, this heterocyclic compound is not substituted in the imine nitrogen with H, methyl, ethyl, propyl or isopropyl, or b) in optionally present groups XNHR4 or XNR4R4' of substituent R2, R4 and/or R4' does not mean C1-4 alkyl, provided that B does not mean COON, SO3H, PO3H2 or tetrazolyl at the same time, and R1 and R2, independently of one another, mean C5-6 heteroaryl or phenyl, if the latter, independently of one another, are unsubstituted, or are substituted simply with C1-6 alkyl, C1-4 perfluoroalkyl, O C1-6 alkyl, O C1-4 perfluoroalkyl, COOH, COO C1-6 alkyl, CO C1-6 alkyl, CONH2, CONHR4, NO2, NH2, NHCOR4, NHSO2R4, or with 1 or 2 halogen atoms from the group that consists of F, Cl, Br, and I, and whereby the following compounds are excluded:
[(1,2-biphenyl-1H-benzimidazol-6-yl)oxy]acetic acid methyl ester, 5-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]pentanoic acid methyl ester, 4-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]butanoic acid ethyl ester, 5-[[1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]-pentanoic acid methyl ester, 6-[[1-(4-nitrophenyl)-2-phenyl-iH-benzimidazol-6-yl]oxy]hexanoic acid methyl ester, 5-[[1-(4-aminophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester, 5-[[1-[4-[[(4-chlorophenyl)sulfonyl]amino]phenyl]-2-phenyl-iH-benzimidazol-6-yl]oxy]pentanoic acid methyl ester, 5-[[1-[4-[(acetyl)amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester 5-[[1-(3-nitrophenyl)-2-phenyl-iH-benzimidazol-6-yl]oxy]pentanoic acid methyl ester, 6-[[1-(3-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester, 5-[[1-(3-aminophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester, 5-[[1-[3-[[(4-chlorophenyl)sulfonyl]amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester, 5-[[1-[3-[(acetyl)amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester.
2. Benzimidazoles according to claim 1, characterized in that R1 means a monocyclic or bicyclic C6-12 aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-2 heteroatoms selected from the group that consists of N, S or O, whereby the above-mentioned aryl or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:
F, Cl, Br, XOH, XOR4, XOCOR4, XOCONHR4, XOCOOR4, XCOR4, XCN, XCOOH, XCOOR4, XCONH2, XCONR4R4, XCONHR4, XCONHOH, XCONHOR4, XCOSR4, XSR4, NO2, XNHR4, XNR4R4', R4 whereby two substituents at R1, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl.
3. Benzimidazoles according to claim 1 or 2, wherein R2 means a monocyclic or bicyclic C6-10 aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-2 heteroatoms selected from the group that consists of N, S or O, whereby the above-mentioned aryl or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:
F, Cl, Br, XOH, XOR4, XOCOR4, XOCONHR4, XOCOOR4, XCOR4, XC(NOH)R4, XC(NOR4)R4', XC(NO(COR4))R4', XCOOH, XCOOR4, XCONH2, XCONHR4, XCONR4R4', XCONHOH, XCONHOR4, XCOSR4, XSR4, XSOR4, XSO2R4, SO2NH2, SO2NHR4, SO2NR4R4', NO2, XNHR4, XNR4R4', XNHSO2R4, XN(SO2R4)SO2R4'; XNR4SO2R4', R4, whereby two substituents at R2, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl.
4. Benzimidazoles according to one of claims 1-3, wherein R3 means one or two substituents, which, independently of one another, can be:
hydrogen, F, Cl, Br, XOH, XOR4, XOCOR4, XOCONHR4, XOCOOR4, XCOR4, XC(NOH)R4, XC(NOR4)R4', XC(NO(COR4))R4', XCN, XSR4, XSOR4, XSO2R4, SO2NH2, SO2NHR4, SO2NR4R4', NO2, XNH2, XNHR4, XNR4N4', XNHSO2R4, XNR4SO2R4', XN(SO2R4)SO2R4', XNHCOR4, XNHCOOR4, XNHCONHR4, or R4, whereby two substituents R3, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, or butane-1,4-diyl.
5. Benzimidazoles according to one of claims 1-4, wherein R4 and R4', independently of one another, mean CF3, C2F5, C1-4-alkyl, C2-4-alkenyl, CZ-4-alkinyl, C3-6-cycloalkyl, (C1-3-alkyl-C3-6-cycloalkyl), phenyl or 5- to 6-membered heteroaryl with 1-2 N, S or O atoms, whereby the phenyl and heteroaryl groups can be substituted with one or two substituents from the group that consists of F, Cl, Br, CH3, C2H5, OCH3, OC2H5, CF3, C2F5, and in addition in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6-membered cycloalkyl ring, one or two ring members can be N
and/or O, whereby ring nitrogens optionally can be substituted with C1-3-alkyl or C1-3-alkanoyl.
6. Benzimidazoles according to one of claims 1-5, wherein R5 and R5', independently of one another, can be C1-6 alkyl, Whereby a carbon atom can be exchanged for O, NH, N C1-3 alkyl , N C1-3 alkanoyl , C3-7 cycloalkyl-C0-3 alkyl, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C1-3 alkyl or C1-3 alkanoyl, whereby the above-mentioned C1-6 alkyl part can be substituted with one of the previously mentioned cycloalkyls or else a 5- to 6-membered heteroaromatic compound with 1-2 heteroatoms, selected from N, S or 0, whereby all previously mentioned alkyl and cycloalkyl parts can be substituted with up to two substituents that consist of CF3, OH, O C1-3 alkyl, and the previously mentioned heteroaryl groups with one or two substituents that consist of F, Cl, CF3, CH3, C2H5, OCH3, OC2H5, or R5 and R5' together with the nitrogen atom form a 5- to 7-membered heterocyclic compound, which can contain another oxygen, nitrogen or sulfur atom and can be substituted with C1-4-alkyl, C1-4-alkoxy-C0-2-alkyl, C1-4-alkoxy-carbonyl, aminocarbonyl or phenyl.
7. Benzimidazoles according to one of claims 1-6, wherein A means C1-10 alkanediyl, C2-10 alkenediyl, C2-10 alkinediyl, (C0-5 alkanediyl-C3-T cycloalkanediyl-C-5 alkanediyl), whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, or in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N
and/or O, whereby ring nitrogens optionally can be -substituted with C1-3 alkyl or C1-3 alkanoyl, whereby in the above-mentioned aliphatic chains, a carbon atom or two carbon atoms can be exchanged for 0, NH, N C1-3 alkyl, or N C1-3 alkanoyl.
8. Benzimidazoles according to one of claims 1-7, wherein B means COOH, COOR5, CONH2, CONHR5, CONR5R5', CONHOH, CONHOR5 or tetrazolyl, in each case bonded to a carbon atom of group A.
9. Benzimidazoles according to one of claims 1-8, wherein X means a bond or methylene.
10. Benzimidazoles according to one of claims 1-9, wherein Y means 0.
11. [(1,2-Diphenyl-1H-benzimidazol-6-yl)oxy]acetic acid isopropyl ester 3-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]propanoic acid methyl ester 2-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]propanoic acid methyl ester 4-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]butanoic acid isopropyl ester 5-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]pentanoic acid isopropyl ester 6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanoic acid methyl ester 6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanoic acid isopropyl ester 6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide N-methoxy-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide N-(phenylmethoxy)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide N-hydroxy-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide 7-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]heptanoic acid methyl ester 6-[[1-(3-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[2-phenyl-1- (3- (trifluoromethyl)phenyl] -1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6- [(2-phenyl-1- [3- (trifluoromethyl)phenyl] -1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[1-(3-cyanophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[(1-(3-cyanophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[(1-(3-cyanophenyl)-2-phenyl-1H-benzimidazol-6-y1] oxy] hexanoic acid 6-((1-(4-cyanophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-(4-cyanophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[1-(3-chlorophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[(1-(3-chlorophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[1-(4-chlorophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-(4-chlorophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[1-(3-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-(3-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-([1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-([1-(3,5-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[(1-(3,5-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[1-(3-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-(3,4-dimethoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-([1-[3,4-(methylenedioxy)phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-([1-[3,4-(methylenedioxy)phenyl]-2-phenyl-1H-benzimidazol-6-yl] oxy] hexanoic acid 6-[[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-([2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yl] oxy] hexanoic acid 6-[[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[1-[4-(N,N-dimethylamino)phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-[4-(N,N-dimethylamino)phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid 6-[[1-phenyl-2-[3-(trifluoromethyl)phenyl]-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[2-(3-chlorophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[2-(3-chlorophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[2-(4-chlorophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[2-(4-chlorophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[2-(4-methylphenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[2-(4-methylphenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[1-phenyl-2-(4-pyridinyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[(1,2-diphenyl-5-nitro-1H-benzimidazol-6-yl)oxy]hexanoic acid methyl ester 6-[(1,2-diphenyl-5-nitro-1H-benzimidazol-6-yl)oxy]hexanoic acid isopropyl ester 6-[[5-[((4-bromophenyl)sulfonyl]amino]-1,2-Biphenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[5-[[(4-chlorophenyl)sulfonyl]amino]-1,2-Biphenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[5-[((4-chlorophenyl)sulfonyl]amino]-1,2-Biphenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[1,2-Biphenyl-5-[((3-methylphenyl)sulfonyl]amino]-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-((1,2-Biphenyl-5-[[(4-methylphenyl)sulfonyl]amino]-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-((1,2-Biphenyl-5-[[(4-methoxyphenyl)sulfonyl]amino]-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[1,2-Biphenyl-5-[[[(4-trifluoromethyl)phenyl]-sulfonyl] amino]-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[5-[[[4-(acetylamino)phenyl]sulfonyl]amino]-1,2-diphenyl-1H-benzimidazol-6-yl]oxy]-hexanoic acid isopropyl ester 6-([5-[[bis(3-chlorophenyl)sulfonyl]amino]-1,2-Biphenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[(1,2-Biphenyl-5-[(propylsulfonyl)amino]-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[5-[(benzylsulfonyl)amino]-1,2-Biphenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 2-(2-[(1,2-Biphenyl-1H-benzimidazol-6-yl)oxy]ethoxy]acetic acid methyl ester 3-[2-[(1,2-Biphenyl-1H-benzimidazol-6-yl)oxy]ethoxy]propanoic acid methyl ester 6-[[1-(3-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid ethyl ester 6-[[4-acetyl-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-5-yl]oxy]hexanoic acid methyl ester 6-[[2-phenyl-1-[4-(thiomethyl)phenyl]-1H-benzimidazol-5-yl]oxy]hexanoic acid methyl ester 6-[[2-phenyl-1-[(4-(thiomethyl)phenyl]-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[2-phenyl-1-(3-thienyl)-1H-benzimidazol-5-yl]oxy]hexanoic acid methyl ester 6-[[2-phenyl-1-(3-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 4-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]butanoic acid methyl ester N-(phenylmethoxy)-6-[[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yl]oxy]-hexanamide N,N-dimethyl-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide N-isopropyl-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide 6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]-1-pyrrolidin-1-ylhexan-1-one 5-[[5-[[(4-chlorophenyl)sulfonyl]amino]-1,2-diphenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester 6-[[5-[[(4-chlorophenyl)sulfonyl]amino]-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[5-[[(4-chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[4-(acetyloxy)-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[4-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[4-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid 6-[[7-methyl-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester
12. 6-[[2-Phenyl-1-(3-pyridyl)-1H-benzimidazol-5-yl]oxy]hexanoic acid methyl ester 6-[[2-phenyl-1-(3-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[2-phenyl-1-(4-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[2-(4-fluoro-phenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[2-(4-methoxyphenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]-hexanoic acid methyl ester 6-[[2-(4-bromophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[2-[4-(trifluoromethyl)phenyl]-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-phenyl-2-(benzothien-2-yl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-phenyl-2-(benzothien-2-yl)-1H-benzimidazol-6-yl]oxy]hexanoic acid 6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid 6-[[5-methoxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester 6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[5-methoxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[5-[[(4-chlorophenyl)sulfonyl]amino]-1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[5-[[(4-chlorophenyl)sulfonyl]amino]-2-(4-fluorophenyl)-1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[5-[[(4-chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 4-[[5-[[(4-chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]butanoic acid methyl ester 5-[[5-[[(4-chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester 5-[[5-[[(4-chlorophenyl)sulfonyl]amino]-1,2-diphenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester 6-[[5-[[(4-(trifluoromethyl)phenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[5-[[(4-chlorophenyl)sulfonyl]methylamino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid 6-[[1-(3-fluorophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[2-(4-nitrophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-phenyl-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester N-(cyclopropylmethoxy)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide N-isobutoxy-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide N-(cyclopropylmethoxy)-6-[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yl)oxy]-hexanamide N-isobutoxy-6-[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yl)oxy]hexanamide N-(2-methoxyethyl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide N-(3-methoxypropyl)-6-((1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide N-isobutyl-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide 6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]-1-morpholin-1-ylhexan-1-one N,N-di(-2-methoxyethyl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide N-isopentyl-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide N-(pyridin-2-yl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide N-(pyridin-3-yl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide N-isopropyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide N,N-dimethyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide N,N-diethyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide N-isobutyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide N-cyclopropyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide N-cyclobutyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide N-tert-butyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide (R)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]1-(2-methoxymethyl)-pyrrolidin-1-ylhexan-1-one N-(3-imidazol-1-yl-propyl)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide N-(2-pyridin-2-ylethyl)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide N-(3-methoxypropyl)-6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yl]oxy]heptanamide 6-[[1-(4-methylphenyl)-2-(3-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-(4-methylphenyl)-2-(4-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-(4-methylphenyl)-2-(2-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-(4-methylphenyl)-2-(3-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[2-(3-indolyl)-1-(4-methylphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-(4-methylphenyl)-2-(2-furyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-(4-methylphenyl)-2-(3-furyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-(4-methylphenyl)-2-(5-methyl-2-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester 6-[[1-(4-methylphenyl)-2-(3-methyl-2-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester.
13. Use of a compound according to one of claims 1-12 for the production of a pharmaceutical agent for treating or preventing diseases that are associated with a microglia activation.
14. Pharmaceutical agent, wherein it contains one or more compounds according to one of claims 1-12 and one or more vehicles.
15. Use of a benzimidazole of general formula II
in which R1 means a monocyclic or bicyclic C6-12-aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-4 heteroatoms selected from the group that consists of N, S or O, whereby the above-mentioned aryl or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:

F, Cl, Br, I, C(NH)NH2, C(NH)NHR4, C(NH)NR4R4', C(NR4)NH2, C(NR4)NHR4', C(NR4)NR4R4', XOH, XOR4, XOCOR4, XOCONHR4, XOCOOR4, XCOR4, XC(NOH)R4, XC(NOR4)R4', XC(NO(COR4))R4', XCN, XCOOH, XCOOR4, XCONH2, XCONR4R4', XCONHR4, XCONHOH, XCONHOR4, XCOSR4, XSR4, XSOR4, XSO2R4, SO2NH2, SO2NHR4, SO2NR4R4', No2, XNH2, XNHR4, XNR4R4', XNHSO2R4, XN(SO2R4)(SO2R4'), XNR4So2R4', XNHCOR4, XNHCOOR4, XNHCONHR4, tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisoindol-1-yl, R4, whereby two substituents at R1, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl, R2 means a monocyclic or bicyclic C6-10 aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-4 heteroatoms selected from the group that consists of N, S or O, whereby the above-mentioned aryl or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:
F, Cl, Br, I, C(NH)NH2, C(NH)NHR4, C(NH)NR4R4', C(NR4)NH2, C(NR4)NHR4', C(NR4)NR4R4', XOH, XOR4, XOCOR4, XOCONHR4, XOCOOR4, XCOR4, XC(NOH)R4, XC(NOR4)R4', XC(NO(COR4))R4', XCN, XCOOH, XCOOR4, XCONH2, XCONR4R4', XCONHR4, XCONHOH, XCONHOR4, XCOSR4, XSR4, XSOR4, XSO2R4, SO2NH2, SO2NHR4, SO2NR4R4', NO2, XNH2, XNHR4, XNR4R4', XNHSO2R4, XN(SO2R4)(SO2R4'), XNR4SO2R4', XNHCOR4, XNHCOOR4, XNHCONHR4, tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisoindol-1-yl, R4, whereby two substituents at R2, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl, R3 stands for one or two substituents, which form, independently of one another:
hydrogen, F, Cl, Br, I, XOH, XOR4, XOCOR4, XOCONHR4, XOCOOR4, XCOR4, XC(NOH)R4, XC(NOR4)R4', XC(NO(COR4))R4', XCN, XCOOH, XCOOR4, XCONH2, XCONHR4, XCONR4R4', XCONHOH, XCONHOR4, XCOSR4, XSR4, XSOR4, XSO2R4, SO2NH2, SO2NHR4, SO2NR4R4', NO2, XNH2, XNHR4, XNR4R4', XNHSO2R4, XNR4SO2R4', XN(SO2R4)(SO2R4'), XNHCOR4, XNHCOOR4, XNHCONHR4, tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisoindol-1-yl, R4, whereby two substituents at R3, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl, R4 and R4', independently of one another, mean C1-4 perfluoroalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkinyl, C3-7 cycloalkyl, (C1-3 alkyl-C3-7 cycloalkyl), C1-3 alkyl-C6-10- aryl, C1-3 alkyl 5 to 10-membered heteroaryl, with 1-4 N, S or O atoms, C6-10-aryl or 5- to 10-membered heteroaryl with 1-4 N, S or O atoms, whereby the C6-10-aryl and heteroaryl groups can be substituted with one or two substituents from the group that consists of F, Cl, Br, CH3, C2H5, NO2, OCH3, OC2H5, CF3, C2F5 or else can carry an annelated methanediylbisoxy group or ethane-1,2-diylbisoxy group, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C1-3 alkyl or C1-3 alkanoyl, R5 and R5', independently of one another, mean hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkinyl, whereby a carbon atom can be exchanged for O, S, SO, SO2, NH, N C1-3 alkyl or N C1-3 alkanoyl, C3-7 cycloalkyl-C0-3 alkyl, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C1-3 alkyl or C1-3 alkanoyl, C6-10 aryl or 5- to 10-membered heteroaryl with 1-4 heteroatoms from N, S, and O, whereby the above-mentioned alkyl, alkenyl and alkinyl chains can be substituted with one of the previously mentioned cycloalkyls, aryls or heteroaryls, whereby all previously mentioned alkyl and cycloalkyl radicals with up to two substituents consisting of CF3, C2F5, OH, O C1-3 alkyl, NH2, NH C1-3 alkyl, NH C1-3 alkanoyl, N (C1-3 alkyl)2, N(C1-3 alkyl)(C1-3 alkanoyl), COOH, CONH2, COO C1-3 alkyl and all previously mentioned aryl and heteroaryl groups can be substituted with one or two substituents from the group that consists of F, Cl, Br, CH3, C2H5, NO2, OCH3, OC2H5, CF3, C2F5 or else can carry an annelated methanediylbisoxy, ethane-1,2-diylbisoxy group, or R5 and R5' together with the nitrogen atom form a 5-to 7-membered heterocyclic compound, which can contain another oxygen, nitrogen or sulfur atom and can be substituted with C1-4-alkyl, C1-4-alkoxy-C0-2-alkyl, C1-4-alkoxy-carbonyl, aminocarbonyl or phenyl, A means C1-10 alkanediyl, C2-10 alkenediyl, C2-10 alkinediyl, (C0-5 alkanediyl-C3-7 cycloalkanediyl-C0-5 alkanediyl), (C0-5 alkanediylarylene-C0-5 alkanediyl), (C0-5 alkanediyl-heteroarylene-C0-5 alkanediyl), whereby the aryl and heteroaryl groups can be substituted with one or two substituents that consist Of F, Cl, Br, CH3, C2H5, NO2, OCH3, OC2H5, CF3, C2F5, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N
and/or O, whereby ring nitrogens optionally can be substituted with C1-3-alkyl or C1-3-alkanoyl, whereby in the above-mentioned aliphatic chains, a carbon atom or two carbon atoms can be exchanged for 0, NH, NR4, NCOR4, NSO2R4, and whereby alkyl or cycloalkyl groups can be substituted with up to two substituents consisting of F, OH, OR4, OCOR4, =O, NH2, NR4R4', NHCOR4, NHCOOR4, NHCONHR4, NHSO2R4 SH, SR4, B means hydrogen, OH, OCOR5, OCONHR5, OCOOR5, COR5, C(NOH)R5, C(NOR5)R5', C(NO(COR5))R5', COOH, COOR5, CONH2, CONHNH2, CONHR5, CONR5R5', CONHOH, CONHOR5, SO3H, SO2NH2, SO2NHR5, SO2NR5R5', PO3H, PO(OH)(OR5), PO(OR5)(OR5'), PO(OH)(NHR5), PO(NHR5)(NHR5'), tetrazolyl, respectively bonded to a carbon atom of group A, or the entire group Y-A-B N(SO2R4)(SO2R4') or NHSO2R4, X means a bond, CH2, (CH2)2, CH(CH3), (CH2)3, CH(CH2CH3), CH(CH3)CH2, CH2CH(CH3), Y means a bond, O, S, SO, SO2, NH, NR4, NCOR4, NSO2R4, for the production of a pharmaceutical agent for treating or preventing diseases that are associated with a microglia activation.
16. Use according to claim 15, whereby in general formula II, R1 means a monocyclic or bicyclic aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-2 heteroatoms selected from the group that consists of N, S or O, whereby the above-mentioned aryl or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:
F, Cl, Br, XOH, XOR4, XOCOR4, XOCONHR4, XOCOOR4, XCOR4, XCN, XCOOH, XCOOR4, XCONH2, XCONR4R44', XCONHR4, XCONHOH, XCONHOR4, XCOSR4, XSR4, NO2, XNHR4, XNR4R4', R4, whereby two substituents at R1, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl.
17. Use according to claim 15 or 16, whereby in general formula II, R2 means a monocyclic or bicyclic aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-2 heteroatoms selected from the group that consists of N, S or O, whereby the above-mentioned aryl group or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:
F, Cl, Br, XOH, XOR4, XOCOR4, XOCONHR4, XOCOOR4, XCOR4, XC(NOH)R4, XC(NOR4)R4', XC(NO(COR4))R4', XCN, XCOOH, XCOOR4, XCONH2, XCONR4R4', XCONHR4, XCONHOH, XCONHOR4, XCOSR4, XSR4, XSOR4, XSO2R4, SO2NH2, SO2NHR4, SO2NR4R4', NO2, XNH2, XNHR4, XNR4R4', XNHSO2R4, XN(SO2R4) (SO2R4'), XNR4SO2R4', XNHCOR4, XNHCOOR4, XNHCONHR4, R4, whereby two substituents at R2, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl.
18. Use according to one of claims 15-17, whereby in general formula II
R3 stands for one or two substituents, which independently of one another, mean:
hydrogen, F, Cl, Br, XOH, XOR4, XOCOR4, XOCONHR4, XOCOOR4, XCOR4, XC(NOH)R4, XC(NOR4)R4', XC(NO(COR4))R4' , XCN, XSR4, XSOR4, XSO2R4, SO2NH2, SO2NHR4; SO2NR4R4', NO2, XNH2, XNHR4, XNR4R4', XNHSO2R4, XNR4SO2R4', XN(SO2R4)(SO2R4'), XNHCOR4, XNHCOOR4, XNHCONHR4, or R4, whereby two substituents R3, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl.
19. Use according to one of claims 15-18, whereby in general formula II
R4 and R4', independently of one another, mean CF3, C2F5, C1-4 alkyl, C2-4 alkenyl, C2-4 alkinyl, C3-6 cycloalkyl, (C1-3 alkyl-C3-6 cycloalkyl), C1-3 alkyl aryl, C1-3 alkylheteroaryl, monocyclic aryl or 5- to 6-membered heteroaryl with 1-2 N, S or O atoms, whereby the aryl and heteroaryl groups can be substituted with one or two substituents from the group that consists of F, Cl, Br, CH3, C2H5, NO2, OCH3, OC2H5, CF3, C2F5 or else can carry an annelated methanediylbisoxy or ethane-1,2-diylbisoxy group, and in addition in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C1-3 alkyl or C1-3 alkanoyl.
20. Use according to one of claims 15-19, whereby in general formula II
R5 and R5', independently of one another, can be C1-6 alkyl, whereby a carbon atom can be exchanged for O, NH, N C1-3 alkyl, N C1-3 alkanoyl, C3-7 cycloalkyl-C0-3 alkyl, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N
and/or O, whereby ring nitrogens optionally can be substituted with C1-3 alkyl or C1-3 alkanoyl, whereby the above-mentioned C1-6 alkyl part can be substituted with one of the previously mentioned cycloalkyls or else a 5- to 6-membered heteroaromatic compound with 1-2 heteroatoms, selected from the group that consists of N, S or O, whereby all previously mentioned alkyl and cycloalkyl parts can be substituted with up to two substituents that consist of CF3, OH, O C1-3 alkyl, and the previously mentioned heteroaryl groups can be substituted with one or two substituents that consist of F, Cl, CF3, CH3, C2H5, OCH3, OC2H5, or R5 and R5' together with the nitrogen atom form a 5-to 7-membered heterocyclic compound, which can contain another oxygen, nitrogen or sulfur atom and can be substituted with C1-4-alkyl, C1-4-alkoxy-C0-2-alkyl, C1-4-alkoxy-carbonyl, aminocarbonyl or phenyl.
21. Use according to one of claims 15-20, whereby in general formula II
A means C1-10 alkanediyl, C2-10 alkenediyl, C2-10 alkinediyl, (C0-5 alkanediyl-C3-7 cycloalkanediyl-C0-5 alkanediyl) , or (C0-5 alkanediyl-heteroarylene-C0-5 alkanediyl), whereby an optionally present heteroaryl group can be substituted with one or two substituents that consist of F, Cl, Br, CH3, C2H5, NO2, OCH3, OC2H5, CF3, C2F5, and in addition in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N

and/or O, whereby ring nitrogens optionally can be substituted with C1-3 alkyl or C1-3 alkanoyl, whereby in an aliphatic chain, a carbon atom or two carbon atoms can be exchanged for O, NH, N C1-3 alkyl, N
C1-3 alkanoyl, NSO2 C1-3 alkyl, and whereby alkyl or cycloalkyl parts can be substituted with up to two F atoms or one of the substituents that consists of OH, O C1-3 alkyl, O C1-3 alkanoyl, =O, NH2, NH C1-3 alkyl, N (C1-3 alkyl) 2, NH C1-3 alkanoyl, N (C1-3 alkyl) (C1-3 alkanoyl) , NHCOO C1-3 alkyl, NHCONH C1-3 alkyl, NHSO2 C1-3 alkyl, SH, S C1-3 alkyl.
22. Use according to one of claims 15-21, whereby in general formula II
B means hydrogen, OH, OCOR5, OCONHR5, OCOOR5, COOH, COOR5, CONH2, CONHR5, CONR5R5', CONHOH, CONHOR5, or tetrazolyl, in each case bonded to a carbon atom of group A.
23. Use according to one of claims 15-22, whereby in general formula II, X means a bond or CH2.
24. Use according to one of claims 15-23, whereby in general formula II, Y means a bond, O, S, NH, NR4, NCOR4 or NSO2R4.
CA2396227A 2000-01-14 2001-01-12 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation Expired - Fee Related CA2396227C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10002898.5 2000-01-14
DE10002898 2000-01-14
PCT/EP2001/000334 WO2001051473A1 (en) 2000-01-14 2001-01-12 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation

Publications (2)

Publication Number Publication Date
CA2396227A1 true CA2396227A1 (en) 2001-07-19
CA2396227C CA2396227C (en) 2012-03-20

Family

ID=7628535

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2396227A Expired - Fee Related CA2396227C (en) 2000-01-14 2001-01-12 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation

Country Status (31)

Country Link
EP (1) EP1246808B1 (en)
JP (1) JP2003523961A (en)
KR (1) KR100703908B1 (en)
CN (1) CN1301975C (en)
AT (1) ATE520669T1 (en)
AU (1) AU782993B2 (en)
BG (1) BG65858B1 (en)
BR (1) BR0107628A (en)
CA (1) CA2396227C (en)
CY (1) CY1112962T1 (en)
CZ (1) CZ303726B6 (en)
DK (1) DK1246808T3 (en)
EA (1) EA006302B1 (en)
EE (1) EE05515B1 (en)
ES (1) ES2372026T3 (en)
HR (1) HRP20020664B1 (en)
HU (1) HU228366B1 (en)
IL (2) IL150150A0 (en)
ME (1) MEP13308A (en)
MX (1) MXPA02005742A (en)
NO (1) NO326408B1 (en)
NZ (1) NZ519326A (en)
PL (1) PL209573B1 (en)
PT (1) PT1246808E (en)
RS (1) RS51860B (en)
SI (1) SI1246808T1 (en)
SK (1) SK287527B6 (en)
TW (1) TWI287005B (en)
UA (1) UA75589C2 (en)
WO (1) WO2001051473A1 (en)
ZA (1) ZA200206470B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855714B2 (en) 2001-07-06 2005-02-15 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
DE10134775A1 (en) * 2001-07-06 2003-01-30 Schering Ag 1-alkyl-2.aryl-benzimidazole derivatives, their use for the manufacture of medicaments and pharmaceutical preparations containing these derivatives
DE10135050A1 (en) * 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- or O-substituted benzimidazole derivatives, their use for the preparation of medicaments and pharmaceutical preparations containing them
US6903126B2 (en) 2001-07-09 2005-06-07 Schering Ag 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
DE10207844A1 (en) 2002-02-15 2003-09-04 Schering Ag 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the preparation of medicaments and pharmaceutical preparations containing these derivatives
DE10207843A1 (en) * 2002-02-15 2003-09-04 Schering Ag Microlia inhibitors for interruption of interleukin 12 and IFN-gamma mediated immune responses
US6962932B2 (en) 2002-02-15 2005-11-08 Schering Aktiengesellschaft 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
EP1608628A2 (en) * 2003-03-17 2005-12-28 Takeda San Diego, Inc. Histone deacetylase inhibitors
SE0302570D0 (en) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302573D0 (en) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
MX2007003105A (en) 2004-09-24 2007-06-07 Aztrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i.
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
JP5255994B2 (en) * 2008-11-04 2013-08-07 国立大学法人 岡山大学 Nuclear receptor ligand
WO2012012478A1 (en) * 2010-07-21 2012-01-26 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
CN102382102B (en) * 2010-09-06 2014-01-08 中国科学院广州生物医药与健康研究院 Amide compound
JP6200903B2 (en) * 2012-02-17 2017-09-20 キネタ フォー エルエルシー Antiviral drugs for the treatment of arenavirus infections
WO2014044611A1 (en) 2012-09-20 2014-03-27 Bayer Pharma Aktiengesellschaft 1-aryl-2-heteroaryl benzimidazoles for the induction of neuronal regeneration
PL3390367T3 (en) * 2015-12-15 2021-03-08 The Board Of Trustees Of The Leland Stanford Junior University Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
BR112021006488A2 (en) 2018-10-05 2021-07-06 Annapurna Bio Inc compounds and compositions for the treatment of conditions associated with apj receptor activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4430502A (en) * 1982-08-13 1984-02-07 The Upjohn Company Pyridinyl substituted benzimidazoles and quinoxalines
DK0520200T3 (en) * 1991-06-24 1998-09-23 Neurosearch As Imadazole compounds, their preparation and use
MX9203323A (en) * 1991-07-11 1994-07-29 Hoechst Ag THE USE OF XANTHINE DERIVATIVES FOR THE TREATMENT OF SECONDARY INJURIES OF THE NERVOUS CELLS AND FUNCTIONAL DISORDERS AFTER CRANIAL-BRAIN TRAUMA.
DE4129603A1 (en) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS
DE4330959A1 (en) * 1993-09-09 1995-03-16 Schering Ag New benzimidazole derivatives, processes for their preparation and their pharmaceutical use
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
NZ270985A (en) * 1994-04-29 1997-06-24 Lilly Co Eli Substituted benzimidazole derivatives; medicaments and preparation of medicaments
WO1997012613A1 (en) * 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
JP2000506529A (en) * 1996-03-11 2000-05-30 イーライ・リリー・アンド・カンパニー Methods for treating or preventing interstitial cystitis

Also Published As

Publication number Publication date
EP1246808B1 (en) 2011-08-17
EP1246808A1 (en) 2002-10-09
SK10002002A3 (en) 2003-02-04
IL150150A (en) 2014-03-31
MXPA02005742A (en) 2002-09-18
KR100703908B1 (en) 2007-04-05
HUP0204011A2 (en) 2003-05-28
UA75589C2 (en) 2006-05-15
MEP13308A (en) 2010-10-10
EA200200742A1 (en) 2002-12-26
DK1246808T3 (en) 2011-12-05
SK287527B6 (en) 2011-01-04
AU782993B2 (en) 2005-09-15
HRP20020664A2 (en) 2005-04-30
NZ519326A (en) 2005-02-25
WO2001051473A8 (en) 2002-01-03
NO20023362D0 (en) 2002-07-12
EE200200390A (en) 2003-10-15
PT1246808E (en) 2011-11-30
HU228366B1 (en) 2013-03-28
ES2372026T3 (en) 2012-01-13
PL356091A1 (en) 2004-06-14
WO2001051473A1 (en) 2001-07-19
ATE520669T1 (en) 2011-09-15
CN1301975C (en) 2007-02-28
HRP20020664B1 (en) 2012-03-31
BG65858B1 (en) 2010-03-31
NO20023362L (en) 2002-09-13
EE05515B1 (en) 2012-02-15
CA2396227C (en) 2012-03-20
IL150150A0 (en) 2002-12-01
NO326408B1 (en) 2008-12-01
CZ20022420A3 (en) 2002-10-16
EA006302B1 (en) 2005-10-27
CY1112962T1 (en) 2016-04-13
YU45702A (en) 2005-03-15
SI1246808T1 (en) 2011-12-30
CN1395568A (en) 2003-02-05
CZ303726B6 (en) 2013-04-10
JP2003523961A (en) 2003-08-12
BR0107628A (en) 2002-10-08
RS51860B (en) 2012-02-29
PL209573B1 (en) 2011-09-30
BG106821A (en) 2003-01-31
HUP0204011A3 (en) 2003-07-28
ZA200206470B (en) 2004-04-28
AU4233201A (en) 2001-07-24
TWI287005B (en) 2007-09-21
KR20020063629A (en) 2002-08-03

Similar Documents

Publication Publication Date Title
CA2396227A1 (en) 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation
RU2326881C9 (en) Condensed derivatives of azolpyrimine with inhibiting properties of phosphatidyl inositol-3-kinase (pi3k)
RU2226529C2 (en) Derivatives of ortho-antranilamide as anti-coagulating agents, pharmaceutical composition and method for treatment
ES2523266T5 (en) Ortho-condensed pyridine and pyrimidine derivatives (for example, purines) as protein kinase inhibitors
RU2003126233A (en) CONDENSED CYCLIC COMPOUNDS AND THEIR USE IN MEDICINE
RU2006127573A (en) TETRAZOL COMPOUNDS AND THEIR APPLICATION AS ANTAGONISTS OF A METABOTROPIC GLUTAMATE RECEPTOR
JP2005508336A5 (en)
JP2004537564A5 (en)
JP2013517283A5 (en)
RU2004127925A (en) N3-Alkylated Benzimidazole Derivatives as Mek Inhibitors
ZA200508623B (en) Use of derivatives of 2,4-dihydro-[1,2,4]triazole-3-thione as inhibitors of the enzyme myeloperoxidase (MPO)
RU2012116877A (en) COMPOUNDS OF 2-PYRIDONE USED AS NEUTROPHIL ELASTASE INHIBITORS
RU2003131693A (en) NEW TYROSINE KINAZ INHIBITORS
JP2007523182A5 (en)
JP2007501189A5 (en)
SI20269B (en) Derivatives of acyl-piperazinil-pyrimidins, preparation thereof and application as medicaments
RU2010137114A (en) AMIDIC DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND WAYS OF THEIR APPLICATION
RU2013132930A (en) Pyrazole derivative
RU2006125446A (en) DERIVATIVES OF N-SUBSTITUTED N-SULFONILAMINOCYCLOPROPANE AND THEIR PHARMACEUTICAL USE
RU2005131165A (en) IMIDAZOLE-4-YLETINYLPYRIDINE DERIVATIVES
JP2007533732A (en) Use of c-kit inhibitors for the treatment of fibrosis
JP2005537323A5 (en)
RU2005103618A (en) INHIBITING CYCLOOXYGENASE-2 (COX-2) PYRIDINE DERIVATIVES
JP2009501216A5 (en)
RU97109847A (en) DERIVATIVES OF AMINOTHETRAZOLE, USEFUL AS A NITROGEN OXIDE SYNTHASE INHIBITORS

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160112